<?xml version="1.0" encoding="UTF-8"?>
<p>Few patients are being treated with gancivlovir, an acyclovir analogue and inhibitor of the Herpesvirus family including cytomegalovirus (CMV). Ganciclovir is approved for the treatment of complications arising from AIDS-associated CMV infection, but in-vitro assays have not shown any inhibition of the cytopathic effects of SARS-CoV [
 <xref rid="B2-ijerph-17-03176" ref-type="bibr">2</xref>]. 
</p>
